Takeda Pharmaceutical (TAK) Total Current Liabilities (2017 - 2026)

Takeda Pharmaceutical's Total Current Liabilities history runs 10 years deep, the most recent figure standing at $15.5 billion for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 5.7% year-over-year to $15.5 billion; the TTM figure through Mar 2026 stood at $15.5 billion (down 5.7% YoY), while the FY2026 annual figure was $16.1 billion, down 1.91% from the prior year.
• Total Current Liabilities was $15.5 billion for Q1 2026 at Takeda Pharmaceutical, down from $17.0 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $18.8 billion in Q1 2023 to a low of $13.8 billion in Q4 2024.
• Historically, Total Current Liabilities has averaged $16.3 billion across 5 years, with a median of $16.0 billion in 2024.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities declined 16.81% in 2024, then increased 22.9% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $15.8 billion in 2022, then slipped by 2.49% to $15.4 billion in 2023, then dropped by 10.62% to $13.8 billion in 2024, then rose by 22.9% to $17.0 billion in 2025, then dropped by 8.66% to $15.5 billion in 2026.
• The last three Total Current Liabilities figures came in at $15.5 billion (Q1 2026), $17.0 billion (Q4 2025), and $14.5 billion (Q3 2025), per Business Quant data.